In a study, the risks for cardiovascular events and all-cause mortality were only a nonsignificant 4% lower for sevelamer vs calcium acetate recipients older than 65 years initiating hemodialysis.
Hemodialysis patients who stayed on the phosphate binder sucroferric oxyhydroxide for 2 years had fewer hospitalizations those who switched to another binder for 2 years.
According to preliminary research, phosphate binders may bind to helpful substances such as vitamin K, but also to harmful ones, such as lipopolysaccharides and advanced glycation end products.
In meta-analyses, elevated FGF23 correlated with 25% and 22% increased risks for all-cause mortality and cardiovascular events, respectively, among patients on maintenance hemodialysis.
In a phase 3 trial, tenapanor, which reduces paracellular phosphate transport in the intestine, lowered elevated serum phosphorus in patients on hemodialysis.
In a new study, patients with serum phosphate levels above 1.78 mmol/L at the start of peritoneal dialysis had a nearly 2-fold increased risk of death.
In a 2-phased trial, hyperphosphatemia and is sequelae developed in a smaller proportion of patients taking activated charcoal compared with placebo recipients.
